Conclusions: In previous studies, anticonvulsant drugs that induce enzymes increase bone degradation by causing vitamin D deficiency. According to the results ...

Conclusions: This study demonstrates that a long-term OXC monotherapy does not appear to have harmful effect on bone health in drug naïve epilepsy patients.

An alternative explanation is that OXC may have a direct effect on bone cell proliferation, leading to reduced growth of human bone cells, as proposed for CBZ ( ...

From the results of different types of new antiseizure medication, oxcarbazepine and topiramate significantly reduced bone mineral density in children, and the ...

In the present study, anti-epileptic drugs altered the calcium, ionized calcium, and 25-OH vitamin-D3 levels of epilepsy patients and resulted in bone loss, ...

19 июн. 2024 г. · ... 18,19 Oxcarbazepine has been associated with reduced BMD, lower 25-OHD levels, and higher bone turnover, 20 reported no decrease in BMD.

The present study shows that oxcarbazepine did not increase bone degradation during 1 year of oxcarbazepine therapy. We think that early mon- itoring of ...

19 янв. 2022 г. · Anti-osteoporotic treatment if bone loss is identified ... fracture risk. Am J ... Essential Reads: Oxcarbazepine (Trileptal) and Pregnancy.

This study evaluated the effects of oxcarbazepine monotherapy on bone turnover in prepubertal and pubertal children. Thirty-four newly diagnosed pedi-.

Oxcarbazepine also significantly reduces 25-hydroxy vitamin-D levels and increases bone-specific alkaline phosphatase, which is a marker of bone formation ( ...